Running head: Myaesthenia gravis exacerbation caused by botulinum toxin-A for treatment of hyperhidrosis.
We present a 17 year old with congenital myasthenia gravis treated with pyridostigmine and 3,4-diaminopyridine who had severe hyperhidrosis of the axillae that had a profound psychosocial and occupational impact. Antiperspirants proved ineffective, aluminium hydroxide preparations were irritant and iontophoresis was not available for this body site.
Following careful consideration, half the typical botulinum toxin (BTX) cumulative dose was delivered intradermally; 50 units (Dysport) per axilla followed by 72 hours inpatient observation. There was no evidence of worsening myasthenic symptoms and significant improvement in hyperhidrosis at four months. A second treatment with 25 units (Xeomin) per axilla was delivered, this resulted in intermittent diplopia and persistent muscle weakness at six months. 3, 4 -diaminopyridine dose was increased, treatment with BTX was discontinued and hyperhidrosis gradually recurred. Inhibition of synaptic release of ACh in the setting of a congenital deficiency of ACh receptors raises a major concern that myaesthenia exacerbation could be precipitated by BTX. Compound heterozygotes with a K373 deletion suffer more severe myaesthenic disease 4 and this may explain the acute sensitivity to BTX in this case.
Although previous reports suggest the effect of BTX-A may be graded by varying the dose and frequency of administration 5 , this has not specifically been explored for hyperhidrosis.
We suspect that prolonged effects of BTX on muscle in this case (6 months) was mediated by the underlying myaesthenic syndrome. It is also possible that the switch from Dysport to Xeomin resulted in a different biofunctional availability of the neurotoxin, however, this is controversial.
Our case highlights that extreme caution is needed when considering BTX in individuals with impaired neuromuscular signalling, and in individuals with significant muscular weakness following BTX, the possibility that BTX has unmasked a subclinical myasthenia should be considered. 6 Figure legends 
